Knockdown of IGF1 and IGFBP3 expression level via applying a CRISPR/Cas9 genome editing system could promote apoptosis in OS cells which in turn leading to downregulating the expression level of ROS and Nrf-2, and thereby enhancing the sensitivity of Graphene Oxide in tumor cells. The gene discussed is IGF1; the disease is neoplasm.